Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹15,262 Cr revenue.
COGS 34.1%, employees 20.6%.
“biosimilar revenues for q two f y twenty six stood at 2,721 crores, representing a 25% year on year increase.”
“Operating revenues stood at 4,296 crores, up 20% year on year as I just mentioned.”
“Core EBITDA was 1,218 crores, which is up 23% year on year with a margin of 28%.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 2.3%▼ | 10.5% |
| ROCE | 3.6%▼ | 13.8% |
| Net Margin | 3.5%▼ | 8.7% |
| EBITDA Margin | 20.6%▲ | 16.0% |
| Debt To Equity | 0.59x▲ | 0.21x |
| Rev Growth 3yr | 25.2%▲ | 5.8% |
| EPS Growth 3yr | 16.1%▲ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹16,827 Cr +10.3% | ₹15,262 Cr +3.4% | ₹14,756 Cr +32.1% | ₹11,174 Cr +36.5% | ₹8,184 Cr +15.2% | ₹7,106 Cr +11.6% | ₹6,367 Cr +15.5% | ₹5,514 Cr |
| Other Income | ₹327 Cr -72.9% | ₹1,208 Cr +39.6% | ₹866 Cr +130.2% | ₹376 Cr +76.7% | ₹213 Cr -16.4% | ₹255 Cr +57.7% | ₹161 Cr +11.8% | ₹144 Cr |
| Total Income | ₹17,154 Cr +4.2% | ₹16,470 Cr +5.4% | ₹15,621 Cr +35.2% | ₹11,550 Cr +37.6% | ₹8,397 Cr +14.1% | ₹7,360 Cr +12.7% | ₹6,529 Cr +15.4% | ₹5,659 Cr |
| COGS | ₹5,764 Cr +10.9% | ₹5,198 Cr +6.1% | ₹4,898 Cr +33.7% | ₹3,663 Cr +34.8% | ₹2,718 Cr +23.1% | ₹2,209 Cr +7.6% | ₹2,052 Cr +8.2% | ₹1,897 Cr |
| ₹16,182 Cr +10.2% | ₹14,680 Cr +4.9% | ₹14,000 Cr +37.3% | ₹10,195 Cr +43.7% | ₹7,096 Cr +14.0% | ₹6,226 Cr +15.7% | ₹5,381 Cr +16.0% | ₹4,639 Cr | |
| Profit Before Tax | ₹687 Cr -63.6% | ₹1,887 Cr +17.2% | ₹1,609 Cr +51.2% | ₹1,064 Cr -10.6% | ₹1,190 Cr +3.8% | ₹1,147 Cr -5.6% | ₹1,215 Cr +0.1% | ₹1,214 Cr |
| Exceptional Items | (₹285 Cr) ↓ Decline | ₹97 Cr ↑ Recovery | (₹12 Cr) +96.0% | (₹291 Cr) -162.3% | (₹111 Cr) ↓ Decline | ₹13 Cr -81.3% | ₹68 Cr -65.3% | ₹195 Cr |
| ₹58 Cr -87.4% | ₹457 Cr +101.1% | ₹227 Cr -10.5% | ₹254 Cr +20.1% | ₹212 Cr -4.5% | ₹222 Cr -29.7% | ₹315 Cr +48.4% | ₹212 Cr | |
| Net Profit | ₹630 Cr -56.0% | ₹1,429 Cr +10.1% | ₹1,298 Cr +101.8% | ₹643 Cr -16.7% | ₹772 Cr -8.8% | ₹846 Cr -2.8% | ₹871 Cr -13.1% | ₹1,003 Cr |
| Profit (Owners) | ₹604 Cr -40.4% | ₹1,013 Cr -0.9% | ₹1,023 Cr +121.0% | ₹463 Cr -28.6% | ₹648 Cr -12.4% | ₹741 Cr -1.0% | ₹748 Cr -17.4% | ₹905 Cr |
| Minority Interest | ₹25 Cr -93.9% | ₹416 Cr +51.1% | ₹275 Cr +52.7% | ₹180 Cr +46.3% | ₹123 Cr +16.6% | ₹106 Cr -13.9% | ₹123 Cr +26.1% | ₹97 Cr |
| Other Comprehensive Income | ₹886 Cr +102.9% | ₹437 Cr +12.9% | ₹387 Cr +404.8% | ₹77 Cr -30.5% | ₹110 Cr -48.6% | ₹215 Cr ↑ Recovery | (₹188 Cr) -160.2% | (₹72 Cr) |
| EPS | ₹4.81 | ₹8.44 | ₹8.52 | ₹3.85 | ₹5.40 | ₹6.17 | ₹6.24 | ₹7.54 |
| Diluted Shares | ₹134 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr | ₹120 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Biocon Limited has informed the Exchange about Investor Presentation
Biocon Limited has informed the Exchange about Schedule of meet
Biocon Limited has informed the Exchange about Schedule of meet
Biocon Limited has informed the Exchange about Transcript
Biocon Limited has informed the Exchange regarding 'Company Statement'.
Biocon Limited has informed the Exchange about Copy of Newspaper Publication on Postal Ballot Notice
Biocon Limited has informed the Exchange about Copy of Newspaper Publication for Financial Results
Biocon Limited has informed the Exchange regarding Notice of Postal Ballot
Biocon Limited has informed the Exchange about Investor Presentation
Monitoring Agency Report
The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: Report. The response from...
Biocon Limited has informed the Exchange regarding 'Company Statement'.
Biocon Limited has informed the Exchange regarding a press release dated April 21, 2026, titled "Biocon Receives Health Canada Approval of Bosaya (Denosumab) and Vevzuo (Denosumab), Biosimilars to P...
Biocon Limited has informed the Exchange regarding 'Intimation of change in name of step-down subsidiary of the Company'.
Biocon Limited has informed the Exchange regarding 'Amendment in Trust Deed'.